NCT03739866 - Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

November 14, 2019

Study Completion Date

June 15, 2020

Conditions

HIV-1 Infection

Interventions

DRUG

Lenacapavir

Administered subcutaneously in the abdomen

DRUG

Placebo

Administered subcutaneously in the abdomen

DRUG

B/F/TAF

50/200/25 mg tablets administered orally once daily

DRUG

TAF

Tablets administered orally

Trial Locations (12)

33401

Triple O Research Institute, P.A., West Palm Beach

34982

Midway Immunology and Research Center, Ft. Pierce

75208

AIDS Arms, Inc., DBA Prism Health North Texas, Dallas

75246

North Texas Infectious Diseases Consultants, P.A., Dallas

76104

Tarrant County Infectious Disease Associates, Fort Worth

77098

The Crofoot Research Center, INC (dba Gordon E. Crofoot MD PA), Houston

90036

Ruane Clinical Research Group, Inc., Los Angeles

90069

Mills Clinical Research, Los Angeles

90502

The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance

95817

One Community, Sacramento

32803-1851

Orlando Immunology Center PA, Orlando

48072-3436

Be Well Medical Center, Berkley